NMR Platform

The NMR platform provides access to two high field and high sensitivity CryoProbe™ NMR spectrometers:

BRUKER 700 MHz Avance III™
4 channels

CryoProbe™ with 1H and 13C high sensitivity cryo-cooled channels + 15N room temperature channel.

The extreme sensitivity of the instrument allows observation of very low concentrated peptides as well as acquiring 3 dimensional sets of data for structural elucidation of proteins, DNA or RNA…

BRUKER 600 MHz Avance I™
4 channels.

CryoProbe™ with 1H, 19F and 13C high sensitivity cryo-cooled channels + 15N room temperature channel.

The outstanding sensitivity of the fluorine channel of this probe make this spectrometer an exceptional instrument for the characterization of fluorinated compounds, proteins, etc…

Access

The platform is available to any internal IGBMC research group as well as to external academic institutions and private companies.
Participation to the costs depend:

  • on the duration of the experiments,
  • on the level of service/expertise provided,
  • with or without operator.

Tarification/proposal can be provided upon request.

The platform is supported by the French Infrastructure for Integrated Structural Biology.

Thus academic or Industry from France and Europe may apply for access to the platform.

Participation to the cost of access is required.

The platform is part of the European Instruct-ERIC infrastructure.

Access to the platform is granted by Instruct via an application proposal submission.

All costs for access/travelling are covered by Instruct (up to a limit).

Contact

For more information, feel free to contact:

Claude LING

IGBMC BIOS-NMR Platform
Pôle API – ESBS
300, boulevard Sébastien Brant
CS 10413
67412 Illkirch 
03 68 85 47 23
ling@igbmc.fr

Collaborations / Clients

Performances are currently/recently delivered to following labs and companies:

Academic

Industry

IGBMC internal collaborations:

  • Yves Nominé – G. Travé team
    Viral Oncoproteins and Domain-motif networks

External labs:

NOVALIX is located on the Illkirch Campus. The company provides services in the biophysics, biology and structural biology domains.

CASC4DE was founded by lab members and provides expertise in development of analytical methods and software and data engineering.

ALMS Therapeutics develops new peptide drug candidates for the treatment of type 2 diabetes.